Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials

JERUSALEM, July 31, 2008 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (http://www.oramed.com), a developer of oral delivery systems, announced today that it will hold a conference call on August 6, 2008 at 10:30 AM EDT to present the results of its Phase 2A clinical trials of its flagship product, ORMD 0801, an oral insulin capsule.

Oramed's Phase 2A trial is focused on assessing the safety and efficacy of ORMD 0801. This study is a continuation of the successfully completed Phase 1 studies in Israel.

 

    Interested parties should dial:
    In the United States: +1-888-668-9141
    All other locations: +972-3-918-0691
    About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.

For more information, please visit http://www.oramed.com

Forward-looking statements

Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking statements. The company undertakes no obligation to update or revise any forward-looking statements.

 

    Company and Investor Relation Contacts:
    Oramed Pharmaceuticals
    Eric Rosenberg
    Cell:   +972-54-566-7713
    Office: +972-2-566-0001
    eric@oramed.com

    Media Contacts:
    Ruder Finn Israel for Oramed
    Matthew Krieger
    Cell:   +972-54-467-6950
    Office: +972-2-589-2003
    matthew@oramed.com

CONTACT: Company and Investor Relation Contacts: Oramed Pharmaceuticals,Eric Rosenberg, Cell: +972-54-566-7713, Office: +972-2-566-0001,; Media Contacts: Ruder Finn Israel for Oramed, MatthewKrieger, Cell: +972-54-467-6950, Office: +972-2-589-2003, eric@oramed.com matthew@oramed.com

Ticker Symbol: (NASDAQ-OTCBB:ORMP),(NASDAQ-OTCBB:ORMP)

Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: July 2008

View comments

Hide
(web2)